The MCT1 inhibitor AZD3965, currently in Phase I/II trials, demonstrates synergistic effects with immune checkpoint inhibitors (ICIs) by reducing TME lactate levels and potentiating anti‒tumor immunity (Beloueche-Babari et al., 2020). Here, SLC16A1 is linked to neoplasm.